Covid-19 Devastated Some Industries But Accelerated AI Use By Companies Across The Country
Verge Genomics Announces the Addition of Steve Kanes to its Board of Directors
Verge Genomics Announces Research Collaboration with the Sheffield Institute for Translational Neuroscience
Verge Genomics joins the Neurofilament Light Surveillance Project to Accelerate New Approaches to Diagnosing and Treating Frontotemporal Dementia
Verge Genomics Announces Publication of New Approach for Uncovering Novel Drug Targets from Human Genetics
Verge Genomics Announces the Addition of Rita Balice-Gordon, PhD, to its Scientific Advisory Board
Verge Genomics Awarded as Technology Pioneer by World Economic Forum
Verge Genomics to advance its inhibitors of PIKfyve for the treatment of ALS and COVID-19
Verge Genomics Announces the Addition of Two Renowned Neuroscience Drug Development Industry Experts to its Advisory Board
Verge Genomics Appoints Jane Rhodes, Ph.D., M.B.A. as Chief Business Officer
Verge Genomics Announces $32 Million Series A to Lead Artificial Intelligence-Driven Drug Discovery
Verge Genomics Announces Landmark Effort to Generate Field's First Single Cell Data from Patients with Parkinson's Disease
Verge Genomics Announces Landmark Effort to Generate Field's First Single Cell Data from Patients with Parkinson's Disease
Verge Genomics joins Genomics England's Discovery Forum to transform pioneering research into frontline patient treatments
Datavant and Verge Genomics Forge Strategic Alliance to Accelerate Drug Development
Verge Genomics Forges Parkinson’s Disease Data Collaborations with the NIH, Scripps, and Dresden University of Technology to Accelerate Preclinical Drug Development
Verge Genomics Announces a Multi-Institution Collaboration with Columbia University, MGH, USC, and University of Michigan to Advance ALS Research
Verge Genomics Appoints Tony Altar, Ph.D., as Chief Scientific Officer
No PhD, “No Fear”: Alice Zhang, 27, Aims Software At Neuro Diseases
Y Combinator spins out biotech on the 'Verge' of genomics-driven drug discovery
